Features | Partner Sites | Information | LinkXpress
Sign In
JIB
BioConferenceLive
GLOBETECH PUBLISHING

First Drug Approved for Preoperative Breast Cancer Treatment

By BiotechDaily International staff writers
Posted on 09 Oct 2013
The US Food and Drug Administration (FDA) has now granted accelerated approval for a drug to be used for high-risk patients with early stage breast cancer in a neoadjuvant setting.

Perjeta (pertuzumab), marketed by Genentech (South San Francisco, CA, USA), a member of the Roche Group, was approved in 2012 for patients with advanced or late-stage (metastatic) HER2-positive breast cancer. Approximately 20% of breast cancers have increased amounts of the HER2 protein. Perjeta’s new use is intended for patients with HER2-positive, locally advanced, inflammatory or early stage breast cancer (tumor greater than 2 cm in diameter or with positive lymph nodes) that are at high risk of having their cancer return or metastasize, or of dying from the disease. It is to be used as part of a complete treatment regimen, in combination with trastuzumab and other chemotherapy prior to surgery and, depending upon the treatment regimen, may be followed by chemotherapy after surgery. Following surgery, patients should continue to receive trastuzumab to complete one year of treatment.

“We are seeing a significant shift in the treatment paradigm for early stage breast cancer,” said Richard Pazdur, MD, director of the Office of Hematology and Oncology Products, FDA Center for Drug Evaluation and Research. “By making effective therapies available to high-risk patients in the earliest disease setting, we may delay or prevent cancer recurrences.’’

In 2012 the FDA issued a draft guidance about the use of pathologic complete response (pCR; defined as the absence of invasive cancer in the breast and lymph nodes) as an endpoint to support accelerated approval of a drug for neoadjuvant treatment of high-risk, early stage breast cancer. Approval for Perjeta is based on a study designed to measure pCR where 417 participants were randomly assigned to receive one of four neoadjuvant treatment regimens: trastuzumab plus docetaxel, Perjeta plus trastuzumab and docetaxel, Perjeta plus trastuzumab, or Perjeta plus docetaxel. About 39% of participants who received Perjeta plus trastuzumab and docetaxel achieved pCR, compared to about 21% who received trastuzumab plus docetaxel. The most common side effects reported in participants receiving Perjeta plus trastuzumab and docetaxel were hair loss, diarrhea, nausea, and a decrease in infection-fighting white blood cells. Other significant side effects included decreased cardiac function, infusion-related reactions, hypersensitivity reactions, and anaphylaxis.

The confirmatory trial for this accelerated approval is being conducted in a study of over 4,800 participants who had prior breast cancer surgery and are at high risk of having their cancer return. The results, expected in 2016, will provide further information on efficacy, safety, and long-term outcomes.

Related Links:

US Food and Drug Administration
Genentech



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: Microcomputed tomography images (top) and histology images (bottom) of the knees of mice fed a very high fat diet containing omega-3 fatty acid supplement (left) or only omega-6 fatty acids (right) after a knee injury. The omega-6 diet showed abnormal bone remodeling and calcified tissue formation in the joint (white arrow). The omega-6 diet also showed significant loss of cartilage (red staining, yellow arrowhead) and increased joint inflammation (Photo courtesy of Duke University).

Dietary Omega-3 Fatty Acids Moderate Severity of Osteoarthritis in a Mouse Model

Researchers working with an osteoarthritis (OA) obese mouse model found that the fat content of the animals' diet contributed more to the development or arrest of OA than did body weight.... Read more

Therapeutics

view channel

Vaccine Being Developed for Heart Disease Close to Reality

The world’s first vaccine for heart disease is becoming a possibility with researchers demonstrating significant arterial plaque reduction in concept testing in mice. Klaus Ley, MD, from the La Jolla Institute for Allergy and Immunology (LA Jolla, CA, USA), and a vascular immunology specialist, is leading the vaccine... Read more

Business

view channel

A Surge in IPOs Revitalize Investments for the Global Pharma and Biotech

Anti-infective drugs, oncology, and pharmaceutical contract laboratories attract the most investment up to now. The intensified private equity and venture capital (PEVC) deal activity in the global healthcare industry during the recession years, 2008–2010, witnessed a waning post-2010. However, the decline in deals... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.